SecBot SecBot

INSM

INSMED Inc
Nasdaq· Pharmaceutical Preparations· Inc. VA· CIK 0001104506 Biotech & Drug Discovery
$122.88 +1.72 (+1.42%)
Nov 16 4:00 PM ET · prev $121.16
Market cap
$25.9B
Large cap
Consensus
Buy
94% Buy or better · 31 analysts
Median target
$195.00
+59% · range $158.00–243.00
1 year
−37.8%
from $197.40 · Nov 17
30 days
+29.0%
from $95.29
52-week range
$91.88–211.41
−42% from high · low Jun 10
Avg volume 20D
3.75M
Oct 29 spike 11.22M
Short interest
14.08M
≈6.4% of shares · +4.5%
Days to cover
3.6
at average volume
Insider net
−$53.0M
0 buyers · 7 sellers · since May 13
New fund stakes
11
Q2 2026 13F · 6 exits
Filing reports
24
analyzed by SecBot
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 2 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/7 ·Next FDA decision date, Jan 28, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $53.0M.

  • InstitutionsMIXED

    Q2 2026: 74 added (11 new), 60 trimmed or exited. Largest new: Maverick Capital $229.3M, Hrt Financial $73.6M.

  • AnalystsBULLISH

    29 of 31 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +4.5% to 14.08M shares. 3.6 days to cover, ≈6.4% of shares.

  • TrendUPTREND

    11% above its 50-day average.

Who's buying

13F· Q2 2026
11
new positions
6
exits
$464.3M
in new stakes · top 8 shown
FundMoveSharesValue
JPMORGAN CHASE & COTRIM10,428,170$1.1B
Capital International InvestorsADD8,238,124$878.3M
AMERIPRISE FINANCIAL INCDOUBLED6,179,571$658.9M
Orbis Allan Gray LtdDOUBLED6,076,487$647.9M
UBS Group AGADD2,584,446$275.6M
MAVERICK CAPITAL LTDNEW2,150,762$229.3M
MILLENNIUM MANAGEMENT LLCADD2,048,005$218.4M
Qube Research & Technologies LtdDOUBLED1,682,334$179.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

31 analysts
Buy 94% rate it Buy or better
Strong Buy8Buy21Hold2Sell0Strong Sell0
12-month targets · 22 analysts

Price is below the lowest target. Median implies +59%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 2, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 21, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 12, 2026Wolfe Research
DOWNGRADE
DOWNGRADEPeer Perform
Oct 12, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 30, 2026Barclays
MAINTAIN
MAINTAINOverweight
Sep 15, 2026Roth Capital
REITERATE
REITERATEBuy
Congressional trades
INSM trades disclosed by members of Congress, with disclosure delay.
1 members · 0 buys / 1 sells
DateMemberType AmountDisclosed
Jun 10, 2026 Josh GottheimerDHouse Joint account · INSMED INC SELL $1K–$15K Jul 7, 2026 +27d

Insider ledger

Form 4
$0
bought · 0 insiders
$53.0M
sold · 7 insiders
DateInsiderTypeValue
Oct 19, 2026
Hudson Paul
Director
Oct 19, 2026
AWARD6,139 sh
Oct 19, 2026
Koppikar Utpal
Director
Oct 19, 2026
AWARD6,139 sh
Sep 9, 2026
Brennan David R
Director
Sep 9, 2026
SELL$3.1M
Aug 17, 2026
SHAROKY MELVIN MD
Director
Aug 17, 2026
SELL$637.6K
Aug 10, 2026
Adsett Roger
Chief Operating Officer
Aug 10, 2026
EXERCISE$1.3M
Aug 10, 2026
Adsett Roger
Chief Operating Officer
Aug 10, 2026
EXERCISE$2.5M
Aug 10, 2026
Adsett Roger
Chief Operating Officer
Aug 10, 2026
SELL$32.0M
Aug 10, 2026
Adsett Roger
Chief Operating Officer
Aug 10, 2026
EXERCISE$1.1M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

11 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
14,080,405
shares short
+4.5%
vs prior settlement
3.6
days to cover
≈6.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 4, 2026 Other
Insmed to Present at November and December 2026 Investor Conferences
BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first g
Nov 3, 2026 SEC
Sara Bonstein, a former officer of Insmed, filed a Form 144 notice of intent to sell 10,261 shares of common stock…
144 · Impact 2/10
Nov 3, 2026 SEC
Patrick Kane filed a Form 3 initial statement of beneficial ownership upon becoming Corporate Controller of Insmed…
3 · Impact 1/10
Oct 29, 2026 SEC
Insmed reported Q3 2026 total revenue of $524.4M, beating the $499.5M consensus, driven by BRINSUPRI sales of $400.1M…
8-K · Impact 6/10
Oct 19, 2026 Insider
Hudson Paul was granted 6,139 shares
Director
Oct 19, 2026 Insider
Koppikar Utpal was granted 6,139 shares
Director
Sep 9, 2026 Insider
Brennan David R sold 25,000 shares
Director @ $124.00 ($3.1M)
Jun 30, 2026 Inst.
JPMORGAN CHASE & CO · TRIM
10,428,170 shares ($1.1B)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Upcoming
Recent
Nov 4, 2026
Press release
Insmed to Present at November and December 2026 Investor Conferences
BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to…
Nov 4, 2026
Clinical Trial
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Phase 2 · COMPLETED
Oct 30, 2026
Trial readout
T-90d Trial Readout: Treprostinil Palmitil (Phase 3)
Trial: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) Sponsor: Insmed Incorporated…
Oct 29, 2026
Earnings result
INSM Q3 2026 Earnings: EPS $-0.46 (-19.8% vs est)
Oct 19, 2026
Press release
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by…

SecBot reports

24 filings · 6 bullish · 3 bearish · 15 neutral
All INSM filing & press-release reports (24)